As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in the coming days, analysts and especially investors will keep their eyes on…
With its pipeline expanding beyond its initial focus on in vivo programming of myeloid cells, for which the company took its initial name, Myeloid Therapeutics has rebranded as Create Medicines…
If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes with its…
Tim Harris, PhDOperating PartnerSV Health Investors Perfect Preparation Prevents Poor Performance.” These five Ps—with maybe a sixth before the word “poor”—is a traditional saying about the need for careful planning…